Takeda’s $4B TYK2 Drug Tops Bristol Myers’ Sotyktu in Head-to-Head Test

Why It Matters

The superior efficacy could shift prescribing away from injectable biologics toward a high‑margin oral option. This would boost Takeda’s revenue potential and further erode Sotyktu’s modest sales.

Key Takeaways

• Zasocitinib achieved 35% PASI 100 response, over double Sotyktu.
• Takeda paid $4 billion upfront for zasocitinib acquisition.
• Oral TYK2 inhibitors market projected to triple in next decade.
• Sotyktu generated $291 million 2025 revenue, now being de‑promoted.

Pulse Analysis

The oral TYK2 inhibitor class has become a focal point for pharmaceutical investment as clinicians seek convenient, non‑injectable alternatives to biologics for chronic inflammatory diseases. Psoriasis, affecting roughly 125 million people worldwide, has traditionally been managed with injectable antibodies such as AbbVie’s Skyrizi and J&J’s Tremfya. Oral agents promise better patient adherence and lower administration costs, driving a market that analysts expect to triple by 2035. Within this landscape, Takeda’s zasocitinib represents a next‑generation molecule designed to deliver deeper skin clearance while maintaining a pill‑based format.

In the recent head‑to‑head trial, zasocitinib delivered a PASI 100 response in 35% of participants, a statistically significant improvement over Sotyktu’s 14% benchmark. The drug also outperformed on secondary measures like PASI 90 and PASI 75, suggesting a broader efficacy profile. Takeda’s $4 billion upfront acquisition from Nimbus Therapeutics underscores the strategic bet on this molecule, especially after its earlier win against Amgen’s Otezla. The data positions zasocitinib to capture market share from both oral competitors and injectable biologics, provided it can demonstrate comparable safety and real‑world effectiveness.

Looking ahead, the upcoming inflammatory bowel disease trial will be critical for expanding zasocitinib’s label beyond plaque psoriasis. Success could cement Takeda’s foothold across multiple autoimmune indications, enhancing the drug’s commercial appeal and justifying the hefty upfront investment. Meanwhile, Bristol Myers Squibb’s decision to scale back Sotyktu promotion reflects the pressure oral therapies now face. If zasocitinib maintains its efficacy edge, it could reshape prescribing habits, accelerate the shift toward oral regimens, and generate a new high‑margin revenue stream for Takeda.